Connect Biopharma (CNTB) Competitors $1.11 +0.12 (+12.12%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends CNTB vs. RAPT, NBTX, ATYR, STRO, BMEA, LFCR, TCRX, CYBN, SOPH, and ACBShould you be buying Connect Biopharma stock or one of its competitors? The main competitors of Connect Biopharma include RAPT Therapeutics (RAPT), Nanobiotix (NBTX), Atyr PHARMA (ATYR), Sutro Biopharma (STRO), Biomea Fusion (BMEA), Lifecore Biomedical (LFCR), TScan Therapeutics (TCRX), Cybin (CYBN), SOPHiA GENETICS (SOPH), and Aurora Cannabis (ACB). These companies are all part of the "pharmaceutical products" industry. Connect Biopharma vs. RAPT Therapeutics Nanobiotix Atyr PHARMA Sutro Biopharma Biomea Fusion Lifecore Biomedical TScan Therapeutics Cybin SOPHiA GENETICS Aurora Cannabis RAPT Therapeutics (NASDAQ:RAPT) and Connect Biopharma (NASDAQ:CNTB) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, risk, community ranking, dividends, valuation, earnings, media sentiment, institutional ownership and profitability. Is RAPT or CNTB more profitable? Connect Biopharma's return on equity of 0.00% beat RAPT Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets RAPT TherapeuticsN/A -89.10% -76.13% Connect Biopharma N/A N/A N/A Does the media prefer RAPT or CNTB? In the previous week, RAPT Therapeutics had 32 more articles in the media than Connect Biopharma. MarketBeat recorded 35 mentions for RAPT Therapeutics and 3 mentions for Connect Biopharma. Connect Biopharma's average media sentiment score of 0.96 beat RAPT Therapeutics' score of 0.13 indicating that Connect Biopharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment RAPT Therapeutics 2 Very Positive mention(s) 5 Positive mention(s) 9 Neutral mention(s) 6 Negative mention(s) 0 Very Negative mention(s) Neutral Connect Biopharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer RAPT or CNTB? RAPT Therapeutics currently has a consensus price target of $9.50, indicating a potential upside of 759.73%. Connect Biopharma has a consensus price target of $8.00, indicating a potential upside of 620.72%. Given RAPT Therapeutics' higher probable upside, analysts plainly believe RAPT Therapeutics is more favorable than Connect Biopharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score RAPT Therapeutics 1 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.08Connect Biopharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, RAPT or CNTB? Connect Biopharma has lower revenue, but higher earnings than RAPT Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRAPT Therapeutics$1.53M25.25-$116.80M-$2.77-0.40Connect BiopharmaN/AN/A-$59.50MN/AN/A Does the MarketBeat Community believe in RAPT or CNTB? RAPT Therapeutics received 71 more outperform votes than Connect Biopharma when rated by MarketBeat users. However, 72.00% of users gave Connect Biopharma an outperform vote while only 63.12% of users gave RAPT Therapeutics an outperform vote. CompanyUnderperformOutperformRAPT TherapeuticsOutperform Votes8963.12% Underperform Votes5236.88% Connect BiopharmaOutperform Votes1872.00% Underperform Votes728.00% Do institutionals and insiders hold more shares of RAPT or CNTB? 99.1% of RAPT Therapeutics shares are held by institutional investors. Comparatively, 58.7% of Connect Biopharma shares are held by institutional investors. 6.6% of RAPT Therapeutics shares are held by company insiders. Comparatively, 22.6% of Connect Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Which has more risk and volatility, RAPT or CNTB? RAPT Therapeutics has a beta of 0.33, indicating that its share price is 67% less volatile than the S&P 500. Comparatively, Connect Biopharma has a beta of -0.31, indicating that its share price is 131% less volatile than the S&P 500. SummaryRAPT Therapeutics and Connect Biopharma tied by winning 7 of the 14 factors compared between the two stocks. Ad DTILet’s be bluntLet me be blunt with you for just a second… You may think you know when and why stocks move, but you’re wrong… Most traders have no idea about the biggest secret Wall Street keeps — even though it’s hiding in plain sight. But once you’ve cracked this code… It could be the breakthrough you need to start targeting $100-$150 a day in the stock market (starting with just $1,000)! Check out the $100 Challenge now Get Connect Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for CNTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CNTB vs. The Competition Export to ExcelMetricConnect BiopharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$61.33M$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E RatioN/A4.4062.6013.00Price / SalesN/A377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book0.619.636.455.92Net Income-$59.50M$154.43M$119.73M$225.73M7 Day Performance-0.89%-9.46%-5.13%-1.34%1 Month Performance-10.48%-7.27%-2.71%1.15%1 Year Performance-45.85%28.13%31.08%24.02% Connect Biopharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CNTBConnect Biopharma3.7539 of 5 stars$1.11+12.1%$8.00+620.7%-44.2%$61.33MN/A0.00110Short Interest ↓News CoverageGap UpRAPTRAPT Therapeutics4.5971 of 5 stars$1.11-14.0%N/A-91.6%$38.56M$1.53M-0.4080Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageNBTXNanobiotix2.3844 of 5 stars$3.93-3.0%N/A-34.5%$185.23M$36.22M0.00100News CoverageATYRAtyr PHARMA3.0018 of 5 stars$2.91-9.1%N/AN/A$243.85M$588,000.00-3.0956Short Interest ↑News CoverageHigh Trading VolumeSTROSutro Biopharma4.3748 of 5 stars$2.89-16.2%N/A+23.0%$236.86M$153.73M-1.80240Analyst RevisionNews CoverageBMEABiomea Fusion3.7157 of 5 stars$6.53-8.2%N/A-30.0%$236.64MN/A-1.6350LFCRLifecore Biomedical2.7141 of 5 stars$6.40-4.2%N/A-13.9%$235.71M$128.26M80.00690TCRXTScan Therapeutics2.4915 of 5 stars$4.41-8.5%N/A-7.2%$233.62M$12.20M-4.16100Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageCYBNCybin1.2993 of 5 stars$11.65+5.9%N/AN/A$232.88MN/A-1.7550Analyst ForecastNews CoverageGap UpHigh Trading VolumeSOPHSOPHiA GENETICS1.8498 of 5 stars$3.53-4.6%N/A-3.6%$230.77M$64.49M-3.24520Short Interest ↑ACBAurora Cannabis0.6614 of 5 stars$4.20-3.2%N/A-9.7%$230.33M$200.35M-5.531,073Short Interest ↑News Coverage Related Companies and Tools Related Companies RAPT Competitors NBTX Competitors ATYR Competitors STRO Competitors BMEA Competitors LFCR Competitors TCRX Competitors CYBN Competitors SOPH Competitors ACB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CNTB) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Connect Biopharma Holdings Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Connect Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
